Avenue Therapeutics Inc represents values of innovation, integrity, and patient-centered care in the pharmaceutical industry. The company is committed to developing and commercializing innovative therapies to address unmet medical needs. Their corporate philosophy revolves around scientific excellence, collaboration with key stakeholders, and a deep dedication to improving the lives of patients. By staying at the forefront of research and development, Avenue Therapeutics strives to deliver transformative solutions while adhering to the highest ethical standards. With a focus on delivering value to patients, healthcare providers, and shareholders, Avenue Therapeutics Inc aims to make a positive impact in the healthcare landscape.

Avenue Therapeutics Inc is primarily present in the United States.

Avenue Therapeutics Inc has achieved significant milestones since its establishment. The company successfully completed a pivotal Phase 3 study for its lead product, intravenous (IV) tramadol for the management of moderate to moderately severe postoperative pain. Additionally, Avenue Therapeutics Inc received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) which outlined certain requirements to support the New Drug Application (NDA) for IV tramadol. The company continues to work towards meeting these requirements and is committed to advancing the development of IV tramadol as a potential non-opioid treatment option for patients in need.

Avenue Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of intravenous (IV) pain management medications. Founded in 2015, the company focuses on providing innovative treatment options for patients suffering from acute pain following surgery or medical procedures. Avenue Therapeutics Inc aims to improve the standard of care in pain management through its unique drug formulations and delivery methods. With a dedicated team of experts and a strong commitment to research and development, the company is actively working towards addressing the unmet needs in pain management and improving patient outcomes. Avenue Therapeutics Inc is poised to make a significant impact in the healthcare industry.

The main competitors of Avenue Therapeutics Inc in the market are pharmaceutical companies such as Pacira Pharmaceuticals, Mallinckrodt Pharmaceuticals, and Heron Therapeutics.

Avenue Therapeutics Inc is primarily active in the pharmaceutical industry.

The business model of Avenue Therapeutics Inc is focused on developing and commercializing intravenous (IV) tramadol, a potential non-opioid pain medication. Tramadol is a centrally acting analgesic that has been approved for the management of moderate to moderately severe pain. Avenue Therapeutics aims to address the unmet need for non-opioid pain relief options through the development and commercialization of IV tramadol. By leveraging their expertise and research in pain management, Avenue Therapeutics is committed to providing patients with effective and safer pain management alternatives while reducing the risks associated with opioid-related medications.

P/E odnos Avenue Therapeutics iznosi -0,04.

KUV kompanije Avenue Therapeutics iznosi 0.

AlleAktien kvalitativni skor za Avenue Therapeutics je 2/10.

Prihod trenutno ne može biti izračunat za Avenue Therapeutics.

Dobit očekivana Avenue Therapeutics je -9,28 mil. USD.

Avenue Therapeutics Inc. is an innovative pharmaceutical company specializing in the development and marketing of analgesics. The company focuses on the needs of patients requiring rapid pain relief, such as after surgeries or severe injuries. Its main product is Tramadol, an opioid analgesic used intravenously and as a supportive therapy for moderate to severe pain. Avenue Therapeutics aims to bring its products to market quickly through a combination of in-house development and acquisitions. It works closely with healthcare providers and utilizes a multi-channel marketing strategy. Research and development are also important components of the company's business model. Overall, Avenue Therapeutics is focused on meeting the pain relief needs of patients and aims to increase its market share through its diversified products and services.

Avenue Therapeutics isplaćuje dividendu od 0 USD raspoređenu preko isplata u toku godine.

Dividenda za Avenue Therapeutics trenutno ne može biti izračunata ili kompanija ne isplaćuje dividendu.

ISIN od Avenue Therapeutics je US05360L2051.

WKN od Avenue Therapeutics je A2JH92.

Oznaka za praćenje akcija kompanije Avenue Therapeutics je ATXI.

U poslednjih 12 meseci, Avenue Therapeutics je isplatio dividendu u iznosu od . To odgovara dividendnom prinosu od oko . Za narednih 12 meseci, Avenue Therapeutics će verovatno isplatiti dividendu od 0 USD.

Dividendski prinos od Avenue Therapeutics trenutno iznosi .

Avenue Therapeutics isplaćuje dividende na kvartalnom nivou. One se isplaćuju u mesecima .

Avenue Therapeutics je isplaćivao dividendu svake godine u poslednjih 0 godina.

Za narednih 12 meseci očekuju se dividende u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

Avenue Therapeutics se svrstava u sektor 'Zdravlje'.

Da biste primili poslednju dividendu od Avenue Therapeutics od 22. 9. 2024. u iznosu od 0 USD, morali ste da imate akciju u depou pre Ex-dana 22. 9. 2024..

Isplata poslednje dividende izvršena je 22. 9. 2024..

U godini 2023 kompanija Avenue Therapeutics je isplatila 0 USD kao dividende.

Dividende od Avenue Therapeutics se isplaćuju u USD.